OBI Pharma, Inc. (TPEX:4174)
Taiwan · Delayed Price · Currency is TWD 44.05
-1.05 (-2.33%)
Feb 11, 2026, 1:30 PM CST
OBI Pharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 49.29 | 62.68 | 41.55 | 4.71 | 18.77 | 140.89 | |
Revenue Growth (YoY) | -29.13% | 50.85% | 781.96% | -74.90% | -86.68% | 2422.13% |
Cost of Revenue | 132.07 | 138.95 | 115.05 | 44.86 | 44.36 | 6.47 |
Gross Profit | -82.78 | -76.27 | -73.5 | -40.14 | -25.59 | 134.42 |
Selling, General & Admin | 309.73 | 326.78 | 319.28 | 309.76 | 240.83 | 290.42 |
Research & Development | 2,018 | 1,968 | 1,697 | 1,773 | 1,450 | 1,310 |
Operating Expenses | 2,331 | 2,295 | 2,016 | 2,083 | 1,690 | 1,600 |
Operating Income | -2,413 | -2,372 | -2,090 | -2,123 | -1,716 | -1,466 |
Interest Expense | -12.88 | -10.65 | -7.94 | -3.99 | -3.8 | -4.18 |
Interest & Investment Income | 31.98 | 40.07 | 92.96 | 49.93 | 6.46 | 43.42 |
Earnings From Equity Investments | -202.45 | -233.18 | -163.58 | - | - | - |
Currency Exchange Gain (Loss) | 5.58 | 25.44 | 13.11 | 156.68 | -42.06 | -124.12 |
Other Non Operating Income (Expenses) | 50.13 | 9.66 | 8.72 | 4.06 | 8.22 | 8.32 |
EBT Excluding Unusual Items | -2,541 | -2,540 | -2,147 | -1,916 | -1,747 | -1,542 |
Gain (Loss) on Sale of Investments | -0.23 | 0.26 | 879.32 | -1.02 | 20.03 | 48.75 |
Gain (Loss) on Sale of Assets | -0.24 | 43.72 | -0.39 | 0.01 | -15.08 | - |
Asset Writedown | - | - | -5.96 | - | - | - |
Other Unusual Items | -3.01 | - | -2 | - | - | - |
Pretax Income | -2,544 | -2,496 | -1,276 | -1,917 | -1,742 | -1,494 |
Income Tax Expense | 3.22 | -3.56 | -9.59 | -17.77 | -24.36 | -3.79 |
Earnings From Continuing Operations | -2,548 | -2,493 | -1,266 | -1,899 | -1,718 | -1,490 |
Minority Interest in Earnings | 186.5 | 182.62 | 219.49 | 285.41 | 187.2 | 111.96 |
Net Income | -2,361 | -2,310 | -1,046 | -1,614 | -1,531 | -1,378 |
Net Income to Common | -2,361 | -2,310 | -1,046 | -1,614 | -1,531 | -1,378 |
Shares Outstanding (Basic) | 129 | 117 | 115 | 111 | 99 | 99 |
Shares Outstanding (Diluted) | 129 | 117 | 115 | 111 | 99 | 99 |
Shares Change (YoY) | 12.94% | 1.99% | 3.12% | 11.65% | 0.18% | 3.56% |
EPS (Basic) | -18.24 | -19.78 | -9.14 | -14.53 | -15.39 | -13.88 |
EPS (Diluted) | -18.24 | -19.78 | -9.14 | -14.53 | -15.39 | -13.88 |
Free Cash Flow | -1,987 | -1,947 | -1,755 | -1,874 | -1,306 | -1,792 |
Free Cash Flow Per Share | -15.35 | -16.67 | -15.32 | -16.88 | -13.13 | -18.05 |
Gross Margin | -167.96% | -121.69% | -176.89% | - | -136.32% | 95.41% |
Operating Margin | -4896.63% | -3783.67% | -5029.70% | -45059.69% | -9141.35% | -1040.47% |
Profit Margin | -4790.78% | -3685.54% | -2518.65% | -34258.46% | -8154.10% | -978.05% |
Free Cash Flow Margin | -4031.85% | -3105.95% | -4223.71% | -39786.71% | -6956.13% | -1272.04% |
EBITDA | -2,242 | -2,210 | -1,911 | -1,935 | -1,559 | -1,299 |
D&A For EBITDA | 170.96 | 161.42 | 179.2 | 188.01 | 157.24 | 167.29 |
EBIT | -2,413 | -2,372 | -2,090 | -2,123 | -1,716 | -1,466 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.